Seaport Therapeutics, Inc. (NASDAQ:SPTX) Given Consensus Rating of “Hold” by Analysts

Seaport Therapeutics, Inc. (NASDAQ:SPTX) has been assigned an average rating of “Hold” from the eleven research firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $37.3333.

Several equities research analysts recently weighed in on the stock. Leerink Partners initiated coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $35.00 price objective for the company. Citigroup started coverage on shares of Seaport Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $35.00 price objective on the stock. Weiss Ratings assumed coverage on Seaport Therapeutics in a research report on Tuesday, August 11th. They set a “sell (d+)” rating on the stock. JPMorgan Chase & Co. started coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They set an “overweight” rating and a $42.00 price target on the stock. Finally, BNP Paribas Exane lowered Seaport Therapeutics to a “market perform” rating in a research report on Tuesday, May 26th.

Seaport Therapeutics Price Performance

SPTX stock opened at $24.91 on Thursday. The company has a fifty day moving average of $22.13. The company has a market capitalization of $1.33 billion and a PE ratio of -2.06. Seaport Therapeutics has a 1 year low of $14.85 and a 1 year high of $28.38.

Seaport Therapeutics (NASDAQ:SPTX) last posted its earnings results on Monday, August 3rd. The company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($1.07). Analysts predict that Seaport Therapeutics will post -4.6 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Robert J. Hombach bought 13,000 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of $18.14 per share, with a total value of $235,820.00. Following the transaction, the director directly owned 13,000 shares in the company, valued at approximately $235,820. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Citadel Advisors LLC acquired a new position in shares of Seaport Therapeutics during the 2nd quarter valued at about $4,152,000. HighTower Advisors LLC acquired a new stake in shares of Seaport Therapeutics during the 2nd quarter worth approximately $362,000. Braidwell LP bought a new stake in shares of Seaport Therapeutics during the second quarter valued at approximately $10,860,000. Alyeska Investment Group L.P. acquired a new position in shares of Seaport Therapeutics in the second quarter valued at $1,629,000. Finally, TRV GP VI LLC acquired a new position in shares of Seaport Therapeutics in the 2nd quarter valued at $44,769,742.

About Seaport Therapeutics

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.